Results 131 to 140 of about 2,435 (141)

Therapeutic Drug Monitoring of Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis: Where Are We Now?

Pharmaceutics, 2022
Eva Choong, Laurent Decosterd, Sylvain Blanchon   +2 more
exaly  

Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two F508del Alleles

American Journal of Respiratory and Critical Care Medicine, 2022
Gesine Hansen, Jens Vogel-Claussen, Mirjam Stahl   +2 more
exaly  

Multimodal analysis of granulocytes, monocytes, and platelets in patients with cystic fibrosis before and after Elexacaftor–Tezacaftor–Ivacaftor treatment

Frontiers in Immunology, 2023
David Messerer, Christian Karl Braun, Markus Huber-Lang   +2 more
exaly  

Elexacaftor/Tezacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the F508del Mutation and Advanced Lung Disease: A 48-Week Observational Study

Journal of Clinical Medicine, 2022
Nicola Ferrara, Vincenzo Carnovale, Paola Iacotucci   +2 more
exaly  

Elexacaftor/tezacaftor/ivacaftor

Reactions Weekly
openaire   +1 more source

Patent Review of Synthetic Routes and Crystalline Forms of the CFTR-Modulator Drugs Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor

Organic Process Research and Development, 2019
David Hughes
exaly  

Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related Events

American Journal of Respiratory and Critical Care Medicine
Bonnie Ramsey, Marcus Mall, Edward Mckone   +2 more
exaly  

Elexacaftor/ivacaftor/tezacaftor

Reactions Weekly, 2020
openaire   +1 more source

Correlation between trough concentration and AUC for elexacaftor, tezacaftor and ivacaftor

Journal of Cystic Fibrosis
, Steffie Vonk, E Marleen Kemper
exaly  

Adverse events to elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis due to elevated drug exposure?: A case series

Journal of Cystic Fibrosis
Renske Van Der Meer
exaly